14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SILO vs MAIA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, MAIA Biotechnology, Inc. (MAIA) captures the overall head-to-head institutional edge over Silo Pharma, Inc. (SILO) on higher Unified Composite conviction (37.6/100 SELL vs. 29.9/100 SELL) after splitting the core matrix 6–2 (led by Valuation Multiples), while SILO wins 2–1 across the 6-pillar growth and valuation breakdown. SILO trades at $1.71 (N/M Forward P/E, -8250.5% operating margin) versus MAIA at $1.11 (1.2x Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: MAIA earns the overall head-to-head edge with a stronger Unified Composite Score (37.6/100 SELL vs. SILO 29.9/100 SELL) and 1.65β · 108% Vol risk profile, whereas SILO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although MAIA compares more favorably head-to-head, both SILO (29.9/100 SELL) and MAIA (37.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SILO vs MAIA. Trailing 12-month operating profitability (SILO -8250.5% vs MAIA 0.0%) and valuation multiples (SILO N/M vs MAIA 1.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $68.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SILO vs MAIA Key Questions & Quantitative Answers
As of Nov 20, 2026, MAIA Biotechnology, Inc. (MAIA) captures the overall head-to-head institutional edge over Silo Pharma, Inc. (SILO) on higher Unified Composite conviction (37.6/100 SELL vs. 29.9/100 SELL) after splitting the core matrix 6–2 (led by Valuation Multiples), while SILO wins 2–1 across the 6-pillar growth and valuation breakdown. SILO trades at $1.71 (N/M Forward P/E, -8250.5% operating margin) versus MAIA at $1.11 (1.2x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: MAIA earns the overall head-to-head edge with a stronger Unified Composite Score (37.6/100 SELL vs. SILO 29.9/100 SELL) and 1.65β · 108% Vol risk profile, whereas SILO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although MAIA compares more favorably head-to-head, both SILO (29.9/100 SELL) and MAIA (37.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
SILO and MAIA split Growth & Scale metrics: SILO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $54,077 TTM revenue (-14.8% gross margin, -8250.5% operating margin), compared with MAIA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SILO generates $54,077 in USD-normalized revenue versus N/A for MAIA. In operating R&D and SG&A reinvestment, SILO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MAIA.
MAIA screens cheaper on headline valuation multiples. SILO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 75.0x EV/Revenue (unreported FCF margin), whereas MAIA trades at 1.2x Forward P/E, 1.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SILO (-91.2% ROE) versus MAIA (-341.5% ROE) capital efficiency.
In options market volatility and institutional positioning, SILO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.73β · 123% Vol realized risk). By comparison, MAIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.65β · 108% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.